# FORM NO. MGT-7

[Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of rule 11of the Companies (Management and Administration) Rules, 2014]



# **Annual Return**

U24231PN1981PLC024251

AAACE4574C

Pre-fill

Form language Refer the instruction kit for filing the form.

# I. REGISTRATION AND OTHER DETAILS

(i) \* Corporate Identification Number (CIN) of the company

Global Location Number (GLN) of the company

\* Permanent Account Number (PAN) of the company

Name of the Registrar and Transfer Agent

(ii) (a) Na

(iii)

(iv)

(a) Name of the company			E PHARMACEUTICALS L	
(b) Registered office address				
'EMCURE HOUSE' T-184, M.I.D.C, BHOSARI, PUNE Maharashtra 411026				
(c) *e-mail ID of the company		compar	ny.secretary@emcure.cc	
(d) *Telephone number with STD co	de	020306	10000	
(e) Website				
Date of Incorporation		16/04/1	981	
Type of the Company	Category of the Company		Sub-category of the Compa	ny

	Public Company	Company limited by shares				Indian Non-Government company			
(v) Wh	ether company is having share ca	pital	۲	Yes	0	No			
(vi) *W	hether shares listed on recognized	d Stock Exchange(s)	0	Yes	۲	No			
(b	) CIN of the Registrar and Transfe	er Agent		U671	90MF	I1999PTC118368		Pre-fill	

Page 1 of 16

LINK INTIME INDIA PRIVATE LIMITI	ED				
Registered office address of the	Registrar and Tra	ansfer Agents			
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli	(West)				
(vii) *Financial year From date 01/04	/2018	(DD/MM/YYYY	) To date	31/03/2019	(DD/MM/YYYY)
(viii) *Whether Annual general meetir	ıg (AGM) held		/es 🔿	No	
(a) If yes, date of AGM	19/08/2019				
(b) Due date of AGM	30/09/2019				
(c) Whether any extension for A	GM granted		) Yes	No	
II. PRINCIPAL BUSINESS AC	TIVITIES OF T	HE COMPAN	IY		

\*Number of business activities 1

	Main Activity group code		Business Activity Code		% of turnover of the company
1	С	Manufacturing	C6	Chemical and chemical products, pharmaceuticals, medicinal chemical and	100

# III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

\*No. of Companies for which information is to be given 22

Pre-fill All

S.No	Name of the company	CIN / FCRN	Holding/ Subsidiary/Associate/ Joint Venture	% of shares held
1	ZUVENTUS HEALTHCARE LIMIT	U85320PN2002PLC018324	Subsidiary	79.58
2	GENNOVA BIOPHARMACEUTIC	U24231PN2001PLC016253	Subsidiary	87.95
3	Heritage Pharma Holdings INC		Subsidiary	100
4	Heritage Pharma Labs Inc.		Subsidiary	100
5	Heritage Pharmaceuticals Inc.		Subsidiary	100
6	Hacco Pharma Inc.		Subsidiary	100
7	Emcure Pharma UK Ltd.		Subsidiary	100

8Tillomed Holdings LimitedSubsidiary1009Tillomed Laboratories LimitedSubsidiary10010Laboratorios Tillomed Spain S.Subsidiary10011Tillomed Italia S.R.LSubsidiary10012Marean Pharmaceuticals Inc.Subsidiary10013Emcure Pharmaceuticals MenaSubsidiary10014Emcure Nigeria LimitedSubsidiary10015Emcure Pharmaceuticals SouthSubsidiary10016Emcure Pharmaceutica LtdSubsidiary99.9917Emcure Pharma Peru S.A.C.Subsidiary99.9918Emcure Pharma Mexico S.A.DESubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary10022Tillomed France SASSubsidiary100				
Image: Constraint of the constra	8	Tillomed Holdings Limited	Subsidiary	100
11Tillomed Italia S.R.LSubsidiary10012Marean Pharmaceuticals Inc.Subsidiary10013Emcure Pharmaceuticals MenaSubsidiary10014Emcure Nigeria LimitedSubsidiary10015Emcure Pharmaceuticals SouthSubsidiary10016Emcure Pharmaceutica LtdSubsidiary99.9917Emcure Pharma Peru S.A.C.Subsidiary99.9918Emcure Pharmaceuticals Pty LtSubsidiary99.9919Emcure NZ LimitedSubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary100	9	Tillomed Laboratories Limited	Subsidiary	100
12Marean Pharmaceuticals Inc.Subsidiary10013Emcure Pharmaceuticals MenaSubsidiary10014Emcure Nigeria LimitedSubsidiary10015Emcure Pharmaceuticals SouttSubsidiary10016Emcure Brasil Farmaceutica LtcSubsidiary99.9917Emcure Pharma Peru S.A.C.Subsidiary99.9918Emcure Pharma Mexico S.A. DESubsidiary99.9919Emcure Pharmaceuticals Pty LtSubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary100	10	Laboratorios Tillomed Spain S.	Subsidiary	100
Image: Constraint of the constra	11	Tillomed Italia S.R.L	Subsidiary	100
14Emcure Nigeria LimitedSubsidiary10015Emcure Pharmaceuticals SouthSubsidiary10016Emcure Brasil Farmaceutica LtdSubsidiary99.9917Emcure Pharma Peru S.A.C.Subsidiary9918Emcure Pharma Mexico S.A. DiSubsidiary99.9919Emcure Pharmaceuticals Pty LtSubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary100	12	Marean Pharmaceuticals Inc.	Subsidiary	100
Image: constraint of the constra	13	Emcure Pharmaceuticals Mena	Subsidiary	100
IndextIndextIndext16Emcure Brasil Farmaceutica LtSubsidiary99.9917Emcure Pharma Peru S.A.C.Subsidiary9918Emcure Pharma Mexico S.A. DESubsidiary99.9919Emcure Pharmaceuticals Pty LtSubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary100	14	Emcure Nigeria Limited	Subsidiary	100
17Emcure Pharma Peru S.A.C.Subsidiary9918Emcure Pharma Mexico S.A. DESubsidiary99.9919Emcure Pharmaceuticals Pty LtSubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary100	15	Emcure Pharmaceuticals South	Subsidiary	100
18Emcure Pharma Mexico S.A. DESubsidiary99.9919Emcure Pharmaceuticals Pty LtSubsidiary10020Emcure NZ LimitedSubsidiary10021Tillomed Pharma GmbHSubsidiary100	16	Emcure Brasil Farmaceutica Lto	Subsidiary	99.99
19     Emcure Pharmaceuticals Pty Lt     Subsidiary     100       20     Emcure NZ Limited     Subsidiary     100       21     Tillomed Pharma GmbH     Subsidiary     100	17	Emcure Pharma Peru S.A.C.	Subsidiary	99
20     Emcure NZ Limited     Subsidiary     100       21     Tillomed Pharma GmbH     Subsidiary     100	18	Emcure Pharma Mexico S.A. DE	Subsidiary	99.99
21     Tillomed Pharma GmbH     Subsidiary     100	19	Emcure Pharmaceuticals Pty Lt	Subsidiary	100
	20	Emcure NZ Limited	Subsidiary	100
22   Tillomed France SAS   Subsidiary   100	21	Tillomed Pharma GmbH	Subsidiary	100
WARE CARTAL REPENTURES AND STUES SECURITIES OF THE COMPANY				

# IV. SHARE CAPITAL, DEBENTURES AND OTHER SECURITIES OF THE COMPANY

# (i) \*SHARE CAPITAL

(a) Equity share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Total number of equity shares	200,000,000	180,852,116	180,852,116	180,852,116
Total amount of equity shares (in Rupees)	2,000,000,000	1,808,521,160	1,808,521,160	1,808,521,160

#### Number of classes

Class of Shares Equity Shares		Issued capital	Subscribed capital	Paid up capital
Number of equity shares	200,000,000	180,852,116	180,852,116	180,852,116
Nominal value per share (in rupees)	10	10	10	10

		1		1
Total amount of equity shares (in rupees)				
	2,000,000,000	1,808,521,160	1,808,521,160	1,808,521,160

## (b) Preference share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid-up capital
Total number of preference shares	0	0	0	0
Total amount of preference shares (in rupees)	0	0	0	0

Number of classes

0

Class of shares	ICapital	Subscribed capital	Paid up capital
Number of preference shares			
Nominal value per share (in rupees)			
Total amount of preference shares (in rupees)			

# (c) Unclassified share capital

Particulars	Authorised Capital
Total amount of unclassified shares	0

## (d) Break-up of paid-up share capital

Class of shares	Number of shares	Total nominal amount	Total Paid-up amount	Total premium
Equity shares				
At the beginning of the year	180,852,116	1,808,521,160	1,808,521,160	
Increase during the year	0	0	0	0
i. Pubic Issues	0	0	0	0
ii. Rights issue	0	0	0	0
iii. Bonus issue	0	0	0	0
iv. Private Placement/ Preferential allotment	0	0	0	0
v. ESOPs	0	0	0	0
vi. Sweat equity shares allotted	0	0	0	0
vii. Conversion of Preference share	0	0	0	0
viii. Conversion of Debentures	0	0	0	0

0 0 0 0 0 80,852,116 0 0 0 0 0 0	0 0 0 0 1,808,521,160 0 0 0 0	0 0 0 0 1,808,521,160 0 0 0	
0 0 0 80,852,116 0 0 0 0	0 0 0 1,808,521,160 0 0 0	0 0 0 1,808,521,160 0 0	0 0 0 0 0 0
0 0 80,852,116 0 0 0	0 0 1,808,521,160 0 0 0	0 0 1,808,521,160 0 0	0 0 0 0 0 0 0
0 80,852,116 0 0 0	0 1,808,521,160 0 0 0	0 1,808,521,160 0 0	0
80,852,116 0 0 0	1,808,521,160 0 0 0	1,808,521,160 0 0	0
0 0 0 0	0 0 0 0	0	0
0 0 0 0	0 0 0 0	0	0
0	0	0	0
0	0	0	0
0	0		0
		0	
0	0		
	C C	0	0
0	0	0	0
0	0	0	0
0	0	0	0
0	0	0	0
	0	0	
	0	0 0 0 0	0         0         0           0         0         0

Class o	f shares	(i)	(ii)	(iii)
Before split /	Number of shares			
Consolidation	Face value per share			
After split /	Number of shares			
Consolidation	Face value per share			

(iii) Details of shares/Debentures Transfers since closure date of last financial year (or in the case of the first return at any time since the incorporation of the company) \*

$\boxtimes$	Nil [Details being provided in a CD/Digital Media]	⊖ Yes	O No	O Not Applicable
	Separate sheet attached for details of transfers	⊖ Yes	🔿 No	

Note: In case list of transfer exceeds 10, option for submission as a separate sheet attachment or submission in a CD/Digital Media may be shown.

Date of the previous	annual general meeting				
Date of registration o	of transfer (Date Month Ye	ar)			
Type of transfe	r 1	- Equity, 2- Preference Shares,3	- Debentures, 4 - Stock		
Number of Shares/ E Units Transferred	Debentures/	Amount per Share/ Debenture/Unit (in Rs.)			
Ledger Folio of Transferor					
Transferor's Name					
	Surname	middle name	first name		
Ledger Folio of Trans	Ledger Folio of Transferee				
Transferee's Name					
	Surname	middle name	first name		

Date of registration c	of transfer (Date Month Year)		
Type of transfe	r 1 - E	quity, 2- Preference Shares,3 -	- Debentures, 4 - Stock
Number of Shares/ E Units Transferred	)ebentures/	Amount per Share/ Debenture/Unit (in Rs.)	
Ledger Folio of Trans	sferor		
Transferor's Name			
	Surname	middle name	first name
Ledger Folio of Trans	sferee	<u> </u>	
Transferee's Name			
	Surname	middle name	first name

# (iv) \*Indebtedness including debentures (Outstanding as at the end of financial year)

Particulars	Number of units	Nominal value per unit	Total value
Non-convertible debentures	0	0	0
Partly convertible debentures	0	0	0
Fully convertible debentures	0	0	0
Secured Loans (including interest outstanding/accrued but not due for payment) excluding deposits			12,333,285,430
Unsecured Loans (including interest outstanding/accrued but not due for payment) excluding deposits			0
Deposit			0
Total			12,333,285,430

#### **Details of debentures**

Class of debentures	Outstanding as at the beginning of the year	-	Decrease during the year	Outstanding as at the end of the year
Non-convertible debentures	0	0	0	0
Partly convertible debentures	0	0	0	0
Fully convertible debentures	0	0	0	0

## (v) Securities (other than shares and depentures)

v) Securities (c	other than shares and	d debentures)		0	
Type of Securities	Number of Securities	Nominal Value of each Unit	Total Nominal Value	Paid up Value of each Unit	Total Paid up Value
Total					

# V. \*Turnover and net worth of the company (as defined in the Companies Act, 2013)

(i) Turnover

24,537,028,378

(ii) Net worth of the Company

17,775,065,395

## VI. (a) \*SHARE HOLDING PATTERN - Promoters

S. No.	Category	Equity	Preference

		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	86,809,260	48	0	
	(ii) Non-resident Indian (NRI)	0	0	0	
	(iii) Foreign national (other than NRI)	0	0	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	
3.	Insurance companies	0	0	0	
4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	
6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	0	0	0	
10.	Others	0	0	0	
	Total	86,809,260	48	0	0

# Total number of shareholders (promoters)

# (b) \*SHARE HOLDING PATTERN - Public/Other than promoters

S. No.	Category	Equity		Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	69,241,092	38.29	0	
	(ii) Non-resident Indian (NRI)	1,128,220	0.62	0	
	(iii) Foreign national (other than NRI)	0	0	0	

	Total	94,042,856	52	0	0
10.	Others	0	0	0	
9.	Body corporate (not mentioned above)	0	0	0	
8.	Venture capital	23,673,544	13.09	0	
7.	Mutual funds	0	0	0	
6.	Foreign institutional investors	0	0	0	
5.	Financial institutions	0	0	0	
4.	Banks	0	0	0	
3.	Insurance companies	0	0	0	
	(iii) Government companies	0	0	0	
	(ii) State Government	0	0	0	
	(i) Central Government	0	0	0	
2.	Government				

## Total number of shareholders (other than promoters)

Total number of shareholders (Promoters+Public/ Other than promoters)

45	
48	

#### VII. \*NUMBER OF PROMOTERS, MEMBERS, DEBENTURE HOLDERS (Details, Promoters, Members (other than promoters), Debenture holders)

Details	At the beginning of the year	At the end of the year
Promoters	3	3
Members (other than promoters)	45	45
Debenture holders	0	0

## VIII. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

## (A) \*Composition of Board of Directors

Category	Number of directors at the beginning of the year		Number of directors at the end of the year		Percentage of shares held by directors as at the end of year	
	Executive	Non-executive	Executive	Non-executive	Executive	Non-executive

A. Promoter	2	0	2	0	48	0
B. Non-Promoter	2	6	2	4	3.67	0.3
(i) Non-Independent	2	2	2	1	3.67	0
(ii) Independent	0	4	0	3	0	0.3
C. Nominee Directors representing	0	0	0	0	0	0
(i) Banks & FIs	0	0	0	0	0	0
(ii) Investing institutions	0	0	0	0	0	0
(iii) Government	0	0	0	0	0	0
(iv) Small share holders	0	0	0	0	0	0
(v) Others	0	0	0	0	0	0
Total	4	6	4	4	51.67	0.3

Number of Directors and Key managerial personnel (who is not director) as on the financial year end date 10

0

## (B) (i) \*Details of directors and Key managerial personnel as on the closure of financial year

Name	DIN/PAN	Designation	Number of equity share(s) held	Date of cessation (after closure of financial year : If any)
Mr. Shreekant Krushnaj	00621568	Director	200,084	
Mr. Berjis Minoo Desai	00153675	Director	192,856	
Mr. Satish Ramanlal Me	00118691	Managing Director	75,724,248	
Dr. Mukund Keshao Gu	00026843	Whole-time directo	295,716	
Mr. Samonoi Sajani Bar	06874206	Director	0	
Mr. Sunil Rajanikant Me	00118469	Whole-time directo	11,085,012	
Mrs. Namita Vikas Thap	05318899	Whole-time directo	6,339,800	
Mr. Humayun Raja Dha	00004006	Director	154,284	
Mr. Sanjay Kumar Chov	ACLPC2022R	Company Secretar	0	
Mrs. Namita Vikas Thap	AEDPM2995R	CFO	6,339,800	

(ii) Particulars of change in director(s) and Key managerial personnel during the year

Name		beginning / during		Nature of change (Appointment/ Change in designation/ Cessation)
Dr. Fakrul Alam Sayeed	07458933	Director	16/07/2018	Cessation
Dr. Girish Laxmikant Te	00455125	Director	12/09/2018	Cessation

# IX. MEETINGS OF MEMBERS/CLASS OF MEMBERS/BOARD/COMMITTEES OF THE BOARD OF DIRECTORS

A. MEMBERS/CLASS /REQUISITIONED/NCLT/COURT CONVENED MEETINGS

Number of meetings held	1				
Type of meeting	Date of meeting	Total Number of Members entitled to	Attendance		
				% of total shareholding	
Annual General Meeting	28/08/2018	48	9	80.94	

### **B. BOARD MEETINGS**

*Number of n	neetings held 4				
S. No. Date of meeting		Total Number of directors associated as on the date of meeting			
		, i i i i i i i i i i i i i i i i i i i	Number of directors attended	% of attendance	
1	26/04/2018	10	5	50	
2	24/07/2018	9	7	77.78	
3	31/10/2018	8	6	75	
4	01/02/2019	8	6	75	

#### C. COMMITTEE MEETINGS

Nu	mber of meeting	gs held		11			
	S. No.	Type of meeting	Date of meeting	Total Number of Members as	Attendance		
			Date of meeting	on the date of the meeting	Number of members attended	% of attendance	
	1	Audit Committe	24/07/2018	3	2	66.67	
	2	Audit Committe	31/10/2018	3	2	66.67	
	3	Audit Committe	01/02/2019	3	3	100	
	4	Corporate Soc	24/07/2018	3	3	100	

S. No.	Type of meeting		Total Number of Members as		Attendance
		Date of meeting	on the date of	Number of members attended	% of attendance
5	Corporate Soc	31/10/2018	3	3	100
6	Corporate Soc	01/02/2019	3	2	66.67
7	Nomination an	26/04/2018	5	5	100
8	Nomination an	24/07/2018	5	4	80
9	Nomination an	31/10/2018	5	3	60
10	Nomination an	01/02/2019	5	5	100

### D. \*ATTENDANCE OF DIRECTORS

		Board Meetings Committee Meetings		gs	Whether attended AGM			
S. No.	Name of the director	Number of Meetings which director was	Number of Meetings	% of attendance	Number of Meetings which Number of director was Meetings		% of attendance	held on
		entitled to attend	attended	allenuarice	entitled to attend	attended	allenuance	19/08/2019
								(Y/N/NA)
1	Mr. Shreekant	4	4	100	11	11	100	Yes
2	Mr. Berjis Mino	4	3	75	8	6	75	No
3	Mr. Satish Rar	4	4	100	5	5	100	Yes
4	Dr. Mukund Ke	4	2	50	0	0	0	Yes
5	Mr. Samonoi S	4	3	75	4	3	75	No
6	Mr. Sunil Raja	4	2	50	3	2	66.67	Yes
7	Mrs. Namita V	4	3	75	3	3	100	Yes
8	Mr. Humayun	4	3	75	7	5	71.43	No

X. \*REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Nil

Number of Managing Director, Whole-time Directors and/or Manager whose remuneration details to be entered

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Mr. Satish Mehta	Managing Direct	119,533,168	38,500,000	0	461,832	158,495,000
2	Dr. Mukund Gurjar	Whole-time Dire	38,110,342.4	0	0	115,000	38,225,342.4
3	Mrs. Namita Thapar	Whole-time Dire	21,291,040	0	0	135,145	21,426,185
4	Mr. Sunil Mehta	Whole-time Dire	18,501,472	0	0	161,636	18,663,108
	Total		197,436,022.4	38,500,000	0	873,613	236,809,635.4
Number c	lumber of CEO, CFO and Company secretary whose remuneration details to be entered						·

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Mrs. Namita Thapar	CFO	21,291,040	0	0	135,145	21,426,185
2	Mr. Sanjay Kumar C	Company Secre	4,530,572.88	0	0	423,652	4,954,224.88
	Total		25,821,612.88	0	0	558,797	26,380,409.88

Number of other directors whose remuneration details to be entered

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Mr. Humayun Dhan	Director	0	3,200,000	0	160,000	3,360,000
2	Mr. Berjis Desai	Director	0	3,800,000	0	200,000	4,000,000
3	Mr. Shreekant Krusl	Director	0	2,900,000	0	340,000	3,240,000
4	Mr. Samonnoi Bane	Director	0	0	0	120,000	120,000
	Total		0	9,900,000	0	820,000	10,720,000

#### XI. MATTERS RELATED TO CERTIFICATION OF COMPLIANCES AND DISCLOSURES

- \* A. Whether the company has made compliances and disclosures in respect of applicable Yes O No provisions of the Companies Act, 2013 during the year
  - B. If No, give reasons/observations

#### XII. PENALTY AND PUNISHMENT - DETAILS THEREOF

(A) DETAILS OF PENALTIES / PUNISHMENT IMPOSED ON COMPANY/DIRECTORS /OFFICERS NI

Page 14 of 16

Name of the	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which penalised / punished		Details of appeal (if any) including present status		
(B) DETAILS OF CO							
Name of the	Name of the court/ concerned	Date of Order	Name of the Act and	Particulars of	Amount of compounding (in		

section under which

offence committed

offence

Rupees)

#### XIII. Whether complete list of shareholders, debenture holders has been enclosed as an attachment

$oldsymbol{ightarrow}$	Yes	Ο	No
S		$\cup$	

company/ directors/ Authority

officers

#### XIV. COMPLIANCE OF SUB-SECTION (2) OF SECTION 92, IN CASE OF LISTED COMPANIES

In case of a listed company or a company having paid up share capital of Ten Crore rupees or more or turnover of Fifty Crore rupees or more, details of company secretary in whole time practice certifying the annual return in Form MGT-8.

Name	Anurag Vyas
Whether associate or fellow	Associate  Fellow
Certificate of practice number	15536

#### I/We certify that:

(a) The return states the facts, as they stood on the date of the closure of the financial year aforesaid correctly and adequately. (b) Unless otherwise expressly stated to the contrary elsewhere in this Return, the Company has complied with all the provisions of the Act during the financial year.

#### Declaration

I am Authorised by the Board of Directors of the company vide resolution no. ..

dated 02/04/2019

(DD/MM/YYYY) to sign this form and declare that all the requirements of the Companies Act, 2013 and the rules made thereunder in respect of the subject matter of this form and matters incidental thereto have been compiled with. I further declare that:

Whatever is stated in this form and in the attachments thereto is true, correct and complete and no information material to 1. the subject matter of this form has been suppressed or concealed and is as per the original records maintained by the company.

03

2. All the required attachments have been completely and legibly attached to this form.

Note: Attention is also drawn to the provisions of Section 447, section 448 and 449 of the Companies Act, 2013 which provide for punishment for fraud, punishment for false statement and punishment for false evidence respectively.

Director	SATISH RAMANLAL MEHTA			
DIN of the director	00118691			
To be digitally signed by	SANJAY KUMAR CHOWDHARY			
<ul> <li>Company Secretary</li> </ul>				
○ Company secretary in pra	actice			
Membership number 12	878	Certificate of practice nu	umber	
Attachments				List of attachments
1. List of share hol	ders, debenture holders	Δ	ttach	MGT-8_EPL_2018-19.pdf
2. Approval letter f	or extension of AGM;	A	ttach	Committee meetings.pdf Shareholders-MGT_7.pdf
3. Copy of MGT-8;		A	ttach	
4. Optional Attache	ement(s), if any	A	ttach	
				Remove attachment
Modi	fy Check	Form	Prescrutiny	Submit

This eForm has been taken on file maintained by the Registrar of Companies through electronic mode and on the basis of statement of correctness given by the company

# MINISTRY OF CORPORATE AFFAIRS

RECEIPT

G.A.R.7

#### SRN: R01057298

Service Request Date : 09/10/2019

### Payment made into : ICICI Bank

#### **Received From :**

TARIES

Address : SWAMI KRUPA, OFFICE NO. 4

799, SADASHIV PETH, GADGIL STREET

PUNE, Maharashtra

India - 411030

#### Entity on whose behalf money is paid

**CIN:** U24231PN1981PLC024251

#### Name : EMCURE PHARMACEUTICALS LIMITED

#### Address : 'EMCURE HOUSE' T-184,

M.I.D.C, BHOSARI,

PUNE, Maharashtra

India - 411026

#### **Full Particulars of Remittance**

Service Type: eFiling

Service Description	Type of Fee	Amount(Rs.)
Fee for Form MGT-7 for the financial year ending on 2019	Normal	600.00
	Total	600.00
Mode of Payment: Internet Banking - ICICI Bank		

Mode of Payment: Internet Banking - ICICI Bank

Received Payment Rupees: Six Hundred Only

Note –The Registrar may examine this eForm any time after the same is processed by the system under Straight Through Process (STP). In case any defects or incompleteness in any respect is noticed by the Registrar, then this eForm shall be treated and labeled as defective and the eForm shall have to be filed afresh with the fee and additional fee, as applicable. (Please refer Rule 10 of the Companies (Registration offices offices and Fees) Rules, 2014)